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ABSTRACT: Introduction: We present a Jordanian man with
the typical LGMD 2L phenotype of early, asymmetric quadri-
ceps weakness and subsequent biceps brachii weakness.
Methods: Case report. Results: Muscle biopsies document a
progressive dystrophic pattern unrelated to known sarcolemmal
defects associated with muscular dystrophy. Genetic testing
revealed novel, heterozygote Anoctamin 5 gene mutations.
Conclusions: This case report expands the known mutations
resulting in LGMD 2L and supports the assertion that Anocta-
min 5 mutations are more prevalent than previously recognized.
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The original description of the Anoctamin 5
(ANO5) mutation associated with limb-girdle mus-
cular dystrophy (LGMD) 2L was published in
2007.1 Jarry et al. described 14 patients from 8
families of French Canadian ancestry.1 Since then,
ANO5 mutations associated with muscular dystro-
phy—both LGMD 2L and Miyoshi-like muscular
dystrophy type 3 (MMD3)—have been described in
more diverse European populations.2–4
The phenotype of LGMD 2L includes adult
onset (ages, 20–50 years; mean, 30 years) with slow
progression of asymmetric quadriceps and biceps
brachii muscle atrophy and weakness. Quadriceps
involvement precedes biceps brachii weakness, and
creatine kinase (CK) is >10 the upper limit of
normal (mean 4,500 IU/L). No significant cardiac
or respiratory muscle involvement has been
reported.1,3,5
A recent publication suggests a founder effect
of the truncating mutation in the Northern Euro-
pean population.3 Furthermore, Hicks et al. report
LGMD 2L may be twice as prevalent as dysferlinop-
athy (LGMD 2B), and, therefore, it is a common
type of adult-onset muscular dystrophy in those of
European ancestry.3
We report a novel mutation in ANO5 associated
with an LGMD 2L phenotype in a man of Jorda-
nian ancestry. This case illustrates a new mutation
in ANO5 associated with the LGMD 2L phenotype.
Additionally, this case demonstrates LGMD 2L in a
man of non-European ancestry.
CASE REPORT
A 37-year-old man presented in December 2002
with a chief complaint of right leg weakness for
the past year. He reported that his right knee
would give out, leading to unexpected falls and dif-
ficulty climbing stairs. He had no sensory symp-
toms, fasciculations, or pain. He had known left
foot drop reported to be secondary to a lumbar
radiculopathy in 1991, which was treated with lum-
bar discectomy and fusion at that time.
Past medical history included Graves disease in
2000, which was treated successfully with radioabla-
tion of the thyroid.
Neither of his deceased parents had a history
of muscle weakness. He currently has 10 siblings
and 45 nieces and nephews without similar weak-
ness. He is originally from Jordan. He moved to
the United States in 1998. He can trace his ances-
try back to the early 1800s and knows of no Euro-
pean ancestors and no consanguinity.
On physical examination in December 2002, he
had normal muscle bulk, tone, and strength in all
muscle groups of the upper extremities. In the
lower extremities, he had bilateral, distal posterior
leg and right quadriceps muscle atrophy. Muscle
tone was normal. His strength—right over left as
graded by medical research council (MRC) scale—
was: hip flexors 4/4þ, knee extensors 4/5, knee
flexors 5/5, ankle dorsiflexion 5/4 (weakness
thought to be from 1991 radiculopathy), foot ever-
sion 5/5, foot inversion 5/5, and plantar flexion
5/5. There was no facial or neck flexion weak-
ness. Tendon reflexes were 2þ at bilateral biceps
brachialis and patellar tendons, but they were
absent at the Achilles tendons. Sensation was pre-
served to light touch, pinprick, vibration, and pro-
prioception bilaterally. Electrodiagnostic testing
demonstrated normal nerve conduction studies of
bilateral sural and left ulnar sensory and bilateral
fibular and tibial and left ulnar motor nerves.
Concentric needle electromyography (EMG) dem-
onstrated abnormal spontaneous activity in the
form of positive sharp waves and fibrillation
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potentials in bilateral vastus medialis, right vastus
lateralis, left anterior tibialis, left first dorsal inter-
osseus of the hand, and thoracic paraspinal
muscles. Voluntary motor unit potentials in limb
muscles were all of decreased amplitude and
increased recruitment, associated with polyphasia.
An MRI of the lumbosacral spine revealed no evi-
dence of lumbar root impingement or central canal
stenosis. Mild bilateral foraminal canal stenosis was
seen at the L5–S1 level. The CK was found to be
elevated at 5303 IU/L. An evaluation of inflamma-
tory and autoimmune markers was negative and
included anti-nuclear antibody, anti-Ro antibody,
anti-La antibody, anti-Smith antibody, anti-ribonu-
cleoprotein antibody, perinuclear anti-neutrophil
cytoplasmic antibody, cytoplasmic anti-neutrophil
cytoplasmic antibody, Westergren sedimentation
rate, liver smooth muscle antibody, and liver mito-
chondrial antibody.
Muscle biopsy of the left vastus lateralis was
completed in February 2003. The left vastus latera-
lis was chosen, because the right vastus lateralis
had recently undergone EMG study and because
electrodiagnostic involvement of the left vastus
medialis suggested diffuse quadriceps involvement.
Light microscopy of muscle tissue revealed degen-
erating myofibers and clusters of regenerating
myofibers. Other abnormalities included frequent
split fibers, variable muscle fiber diameter, whorled
fibers, and internalized nuclei (Fig. 1A). Some
fibers were surrounded and invaded by inflamma-
tory cells, and rare muscle fibers had small
vacuoles (reported but not pictured here). Stand-
ard muscle stains of Gomori trichrome, Congo
red, oil red O, PAS with and without diastase
revealed no further abnormalities. Histochemical
reactions (ATPase at pH 9.4, 4.6, and 4.2; toluidine
blue, myophosphorylase, myoadenylate deaminase,
phosphofructokinase, NADH-TR, cytochrome C ox-
idase [CCO], succinic dehydrogenase [SDH], com-
bined CCO/SDH, alkaline and acid phosphatases,
nonspecific esterase) also revealed no further
abnormalities than those noted above. Additional
assessment for a muscular dystrophy through im-
munohistochemical staining was pursued and was
negative; immunohistochemical stains included
FIGURE 1. Light microscopy of left vastus lateralis muscle biopsies. (A) Biopsy of left vastus lateralis in 2003 shows myopathic fea-
tures including muscle fiber degeneration and regeneration (arrows). An increase in internalized nuclei, slight fiber hypertrophy and
fiber splitting are present. Fiber sizes vary from less than 30 to 100 microns. Scale bar ¼ 50 microns. (B) Biopsy of left vastus lateralis
in 2006 shows marked increase in endomysial collagen and fiber size variation (less than 10 to 115 microns). Some of the largest
fibers are whorled fibers. Internalized nuclei are more frequent, and many individual fibers have greater than 2 Internalized nuclei.
Nuclear myobags (arrows) are present. Scale bar ¼ 50 microns. (C) Endomysial inflammation (arrow) is prominent, 2006. Scale bar ¼
100 microns. (D) Succinic dehydrogenase stain highlights large whorled fibers (arrows), 2006. Scale bar ¼ 20 microns.
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dysferlin, caveolin 3, sarcoglycans (alpha, beta,
delta, gamma), dystrophin, emerin, merosin, lami-
nin, lamin A/C, myotilin, and beta-dystroglycan,
and all were equivalent to that of control muscle.
No further testing for muscular dystrophy was
done, and the patient began treatment for a possi-
ble idiopathic inflammatory myopathy in April
2003. He was treated initially with oral prednisone
60 mg daily, and it was later combined with oral
methotrexate up to 25 mg weekly. He continued
to progress slowly with increasing weakness of his
right quadriceps. His CK remained elevated, typi-
cally between 3,000 and 6,000 IU/L with an outlier
of 9,000 IU/L after exercise.
We initially met and evaluated the patient in
2006. His examination at that time continued to
show full strength in facial muscles, neck flexors,
and upper extremity muscles. Bilateral quadriceps
atrophy was now present, and he had asymmetrical
knee extension and flexion weakness, greater on
the right. Bilateral dorsiflexion weakness was
noted. Reflexes were 2þ at biceps brachii, 1þ at
patellae, and absent at the Achilles tendon. Sensa-
tion remained intact to multiple modalities as
recorded before. We questioned the utility of con-
tinuing immunosuppression given his progressive
weakness and muscle atrophy with continued CK
elevation. We performed a repeat biopsy of the left
vastus lateralis muscle in August 2006. The find-
ings were consistent with muscular dystrophy with
marked myofiber replacement (up to 50%) by con-
nective tissue (Fig. 1B and C). Inflammatory infil-
trates were still seen, as was a more progressive
stage of myofiber size variability and splitting (Fig.
1C). Large whorled fibers were present. Several
CCO-negative fibers were seen. The pathological
progression of dystrophic changes and lack of
response to immunosuppressive therapy led to fur-
ther testing for muscular dystrophies. Sequencing
of genes for fukutin-related protein, calpain-3,
lamin A/C, caveolin-3, alpha-sarcoglycan and dys-
trophin were normal. Monocyte dysferlin levels
were normal. Genetic testing for facioscapulohum-
eral muscular dystrophy (FSHD) was negative. He
continued to be followed in our clinic for the diag-
nosis of unspecified muscular dystrophy and devel-
oped symptoms of prominent and progressive
quadriceps weakness with bilateral foot drop and
plantar flexion weakness. In 2009 he developed
mild weakness of bilateral biceps brachii. Motor ex-
amination in November 2011 revealed muscle atro-
phy in the bilateral supraspinati, pectoral, and
biceps brachii muscles in the arms and in bilateral
quadriceps, hamstrings, and anterior and posterior
muscles in the lower legs (Fig. 2). On strength test-
ing, there was mild weakness of bilateral biceps
brachii and supraspinati with preserved function in
the deltoid, triceps, and distal upper extremity
muscles. Lower extremity weakness was graded as
follows (R/L): hip flexion 4/4, knee extension 2/
2, knee flexion 4/3, dorsiflexion 3/0, and plantar
flexion 4/4. The patient remained ambulatory
without an assistive device, but had significant diffi-
culty arising from a seated position, marked diffi-
culty with steps, and significant hyperextension at
both knees with casual gait. He had no symptoms
of cardiac or respiratory dysfunction. CK levels
remain elevated at approximately 3,000–4,000 IU/
FIGURE 2. Muscular atrophy—patient photos. (A) Atrophy of anterior and posterior compartments of lower leg, quadriceps and ham-
string muscles. (B) Quadriceps atrophy. (C) Atrophy of shoulder girdle muscles. (D) Atrophy of biceps and pectoral muscles: the
patient’s left upper limb is more affected than the right.
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L. Of interest, he incidentally had an MRI of his
left knee after a motor vehicle accident in 2008.
Note was made of severe atrophy of quadriceps,
hamstrings, gastrocnemius, tibialis anterior, and
extensor digitorum longus muscles with relative
sparing of the sartorius, popliteus, and fibularis
longus and brevis muscles (Fig. 3).
Given his evolving phenotype of early asymmet-
ric quadriceps weakness, later biceps brachii weak-
ness, and high CK, he underwent ANO5 gene
sequencing by means of Prevention Genetics,
Marshfield WI, USA in September 2011. Genomic
DNA was amplified and sequenced of the full cod-
ing regions of the ANO5 exons and approximately
50 base pairs flanking the noncoding sequences.
Our patient was found to have 2 heterozygous
ANO5 mutations that were previously unreported.
One mutation, c.352delG, is expected to result in
a frameshift mutation with early stop codon
(p.Glu118LysfsStop23) and subsequent truncation
of the anoctamin protein. The other mutation is a
base pair substitution, c.1025G>A, on exon 11 of
the ANO5 gene that results in an amino acid
substitution.
DISCUSSION
ANO5 codes for a member of the anoctamin family
of proteins, which comprise 10 members. The
structure of anoctamin is that of a transmembrane
protein with 8 hydrophobic transmembrane seg-
ments with 1 re-entry loop, cytosolic N and C ter-
minals, and a relatively preserved domain of
unknown function (DUF). Transmembrane seg-
ments contain the most-conserved sequences of
amino acids. Ion channel function is postulated
for the anoctamin family. ANO1 and ANO2 are
known calcium-activated chloride channels; ANO6
and ANO7 produce chloride currents; ANO9 and
ANO10 suppress chloride currents under certain
conditions.6 The anoctamins have diverse roles in
various tissues and are believed to play a role in
gut motility, vascular smooth muscle function,
nociception, sensory transduction, metastasis in
several cancers, musculoskeletal disorders (muscu-
lar dystrophy and skeletal development), blood
clotting and cerebellar ataxia.7
An ANO5 (GDD1) mutation underlies the auto-
somal dominant skeletal disorder of gnathodiaphy-
seal dysplasia, which is characterized by skeletal
abnormalities, fibro-osseus lesions of jawbones, and
predisposition to jaw infection and recurrent osteo-
myelitis. Investigation of this disease has led to
interesting insight into ANO5 expression in mus-
cle, noting myotomal expression of ANO5 (GDD1)
during mouse development and upregulation of
ANO5 (GDD1) protein levels in dystrophin-defi-
cient mice.8
ANO5 is predicted to have several alternatively
spliced isoforms. ANO5 mutations are known to
result in autosomal recessive muscular dystrophies
of 2 phenotypes: LGMD 2L and MMD3.5 Some
authors describe LGMD 2L and MMD3 as separate
phenotypes, where MMD3 presents with calf atro-
phy and plantar flexion weakness starting before
asymmetrical quadriceps weakness, while LGMD
2L presents with asymmetric quadriceps and biceps
brachii atrophy and weakness with mild plantar
flexion weakness.5 Other authors note that initial
symptoms of predominant distal or proximal weak-
ness may vary, but LGMD 2L and MMD3 pheno-
types overlap substantially over time.3 Hicks et al.
also report that 85% of LGMD 2L patients may
have early difficulty walking on toes with calf atro-
phy. Because our patient had only mild plantar
flexion weakness at the time of significant, asym-
metrical quadriceps weakness, we believe he falls
FIGURE 3. Muscle atrophy – MRI imaging. (A) MRI of left thigh in cross section shows severe muscle atrophy with relative sparing of
the sartorius muscle (a, vastus lateralis; b, biceps femoris; c, semimembranosus; d, semitendinosus; e, gracilis; f, sartorius; g, vastus
medialis; h, joint effusion). (B) MRI of left lower leg in cross section shows severe muscle atrophy (i, tibialis anterior; j, extensor digito-
rum longus; k, fibularis longus and brevis; l, lateral head of gastrocnemius; m, medial head of gastrocnemius; n, popliteus).
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into the LGMD 2L phenotype. The LGMD 2L phe-
notype has some overlap with dysferlinopathy
(LGMD 2B) with the combination of both distal
and proximal lower limb weakness. Dysferlinopathy
is believed to result from defective participation of
dysferlin in the sarcolemmal repair process respon-
sible for maintaining the sarcolemma in the face
of injuries imposed by high mechanical stress.
Electron microscopy in an LGMD 2L patient and a
MMD3 patient have demonstrated multifocal dis-
ruption of the sarcolemmal membrane. Defective
membrane repair was demonstrated in fibroblasts
of a person with MDD3.2,5 Thus, defective sarco-
lemmal membrane repair has been suggested as
a possible mechanism for ANO5 associated
myopathies.
Muscle biopsies of patients with LGMD 2L and
MMD3 have demonstrated dystrophic changes with
increase in endomysial connective tissue, muscle
fiber size variation, degeneration and regeneration
of muscle fibers, internalized nuclei, and fiber
splitting. Mild focal inflammation was noted in a
case of a severely affected patient, although a
larger study demonstrated inflammatory infiltrates
in 6 of 19 (31%) patients.1,3 Rimmed vacuoles
have been noted in 2 patients, and congophilic
deposits in intramuscular blood vessels and the
interstitium were seen in another patient.3,9 Exclu-
sions have been deficiencies in dystrophin, dysfer-
lin, and sarcoglycans. Electron microscopy in 2 sep-
arate reports has demonstrated reduplicated
basement membrane associated with multifocal
loss of sarcolemmal membrane.1,2
The most commonly reported genetic mutation
producing LGMD 2L is a truncating mutation,
c.191dupA in exon 5; it has been seen in 20 of 64
patients from Germany and the United Kingdom,
with homozygosity in 15 of the patients and com-
pound heterozygosity in another 5. This mutation
may result from a founder effect in the Northern
European population.3 Several other mutations in
ANO5 have also been reported, many in combina-
tion with the c.191dupA mutation, which is believed
to produce disease when it is homozygous or com-
pound heterozygous with other mutations.2,3,5,9
Like c.191dupA, our patient’s heterozygous ANO5
mutation, c.352delG, also predicts a frame shift
mutation and protein truncation. Therefore, given
our patient’s phenotype, the novel c.352delG het-
erozygote mutation on exon 6 of the ANO5 gene is
likely associated with LGMD 2L.
Additionally, our patient also had a heterozy-
gous base pair substitution, c.1025G>A on exon 11
of the ANO5 gene. This mutation results in an
amino acid substitution p.Cys342Tyr. The p.Cys342
residue is in a known, highly conserved region of
the anoctamin-5 protein across humans, primates,
and nonprimate mammals, as well as the lizard,
chicken, frog, and fish. Loss of a cysteine amino
acid would alter disulfide bonds known to be cru-
cial for proper protein folding. Further analysis of
this amino acid substitution by Prevention Genet-
ics, Marshfield, WI using the program PolyPhen-2
predicts the p.Cys342Tyr substitution to be ‘‘prob-
ably damaging’’ to the function of anoctamin-5.10
Therefore, given our patient’s phenotype, the
novel c.1025G>A, heterozygous ANO5 mutation is
also likely to be associated with LGMD 2L. To our
knowledge this is the first patient with LGMD 2L
phenotype and compound heterozygous ANO5
mutations reported in an individual with non-Euro-
pean ancestry. Initially described in several French-
Canadian families, LGMD 2L with underlying
ANO5 mutations is now recognized in Northern
European populations, and its prevalence may be
relatively high among the more common LGMD
syndromes. Our case underscores that LGMD 2L
may be present in an even broader population
than is currently recognized, and further disease-
causing ANO5 mutations may come to light.
Screening for ANO5 is recommended in cases with
the appropriate phenotype, given the potential
prevalence of this LGMD.
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